NO2016025I1 - - Google Patents

Info

Publication number
NO2016025I1
NO2016025I1 NO2016025C NO2016025C NO2016025I1 NO 2016025 I1 NO2016025 I1 NO 2016025I1 NO 2016025 C NO2016025 C NO 2016025C NO 2016025 C NO2016025 C NO 2016025C NO 2016025 I1 NO2016025 I1 NO 2016025I1
Authority
NO
Norway
Application number
NO2016025C
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2016025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of NO2016025I1 publication Critical patent/NO2016025I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO2016025C 2003-09-03 2016-12-20 NO2016025I1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (1)

Publication Number Publication Date
NO2016025I1 true NO2016025I1 (no) 2016-12-20

Family

ID=34280181

Family Applications (6)

Application Number Title Priority Date Filing Date
NO20061374A NO334877B1 (no) 2003-09-03 2006-03-27 Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
NO2014032C NO2014032I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
NO2014031C NO2014031I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino-2-pyrimidinyl]-amino]-benzonitril (Rilpivirie) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpiverine innbefattende hydrokloridsaltet av Rilpivirine, og Temofovir disproksil (spesielt Tenofovir disproksil fumaratsalt).
NO2014030C NO2014030I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
NO2016026C NO2016026I1 (no) 2003-09-03 2016-12-20 Kombinasjon av rilpivirine eller en terapeutisk ekvivalent form derav så som et farmasøytisk akseptabelt salt av rilpivirine innbefattende hydrokloridsaltet av rilpivirine samt emtricitabine samt tenofovir alafenamid eller et farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamid fumarat
NO2016025C NO2016025I1 (no) 2003-09-03 2016-12-20

Family Applications Before (5)

Application Number Title Priority Date Filing Date
NO20061374A NO334877B1 (no) 2003-09-03 2006-03-27 Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
NO2014032C NO2014032I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
NO2014031C NO2014031I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino-2-pyrimidinyl]-amino]-benzonitril (Rilpivirie) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpiverine innbefattende hydrokloridsaltet av Rilpivirine, og Temofovir disproksil (spesielt Tenofovir disproksil fumaratsalt).
NO2014030C NO2014030I1 (no) 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
NO2016026C NO2016026I1 (no) 2003-09-03 2016-12-20 Kombinasjon av rilpivirine eller en terapeutisk ekvivalent form derav så som et farmasøytisk akseptabelt salt av rilpivirine innbefattende hydrokloridsaltet av rilpivirine samt emtricitabine samt tenofovir alafenamid eller et farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamid fumarat

Country Status (25)

Country Link
US (9) US20080200435A1 (no)
EP (1) EP1663240B2 (no)
JP (3) JP5507791B2 (no)
KR (1) KR20060090658A (no)
CN (1) CN101060844B (no)
AP (1) AP2109A (no)
AU (5) AU2004268390B2 (no)
BE (1) BE2015C053I2 (no)
CA (1) CA2537095C (no)
CY (5) CY2015040I1 (no)
FI (1) FI1663240T4 (no)
FR (3) FR15C0071I2 (no)
HK (1) HK1092698A1 (no)
HR (1) HRP20150798T4 (no)
HU (5) HUS1500054I1 (no)
IL (2) IL173438A (no)
LT (2) LTPA2016045I1 (no)
LU (3) LU92853I2 (no)
MX (1) MXPA06002437A (no)
MY (1) MY169670A (no)
NL (2) NL300781I1 (no)
NO (6) NO334877B1 (no)
NZ (1) NZ545306A (no)
PL (1) PL1663240T5 (no)
WO (1) WO2005021001A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EP1529032B1 (en) 2002-08-09 2013-04-24 Janssen Pharmaceutica NV Processes for the preparation of 4- 4- 4-(2 -cyanoethenyl)-2,6-dimethylphenyl )amino) -2-pyrimidinyl)amino benzonitrile
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
SI1632232T1 (sl) * 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
KR101276571B1 (ko) * 2004-09-02 2013-06-18 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
AU2005279158C1 (en) * 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
BRPI0514861A (pt) * 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080091767A (ko) * 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
TWI458483B (zh) * 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
PL2234620T3 (pl) * 2008-01-03 2016-09-30 Trójterapia użyteczna przy leczeniu pacjenta zakażonego wirusem hiv
KR101726615B1 (ko) * 2008-12-24 2017-04-13 얀센 사이언시즈 아일랜드 유씨 Ｈｉｖ 치료용 체내 임플란트 장치
WO2011080141A2 (en) 2009-12-21 2011-07-07 Tibotec Pharmaceuticals Degradable removable implant for the sustained release of an active compound
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
SG10201509521WA (en) * 2010-11-19 2015-12-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2757560T3 (es) 2015-11-09 2020-04-29 Gilead Sciences Inc Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
ES2970870T3 (es) 2016-10-24 2024-05-31 Janssen Sciences Ireland Unlimited Co Composiciones dispersables
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
EP3612226A1 (en) 2017-04-18 2020-02-26 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
JP2023503403A (ja) 2019-11-29 2023-01-30 シピオ ライフ サイエンシズ リミテッド リルピビリンを含む組成物及び腫瘍又は癌を治療するためのその使用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5316773A (en) 1990-07-19 1994-05-31 Otsuka Pharmaceutical Co., Ltd. Particulate preparation containing a flourracil derivative and hydroxypropylmethyl-cellulose
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
ATE184787T1 (de) 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU7984200A (en) 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
SK12822002A3 (sk) 2000-03-30 2003-02-04 Bristol-Myers Squibb Company Perličky s trvalým uvoľňovaním obsahujúce stavudín
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CA2431319A1 (en) 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
EP1529032B1 (en) 2002-08-09 2013-04-24 Janssen Pharmaceutica NV Processes for the preparation of 4- 4- 4-(2 -cyanoethenyl)-2,6-dimethylphenyl )amino) -2-pyrimidinyl)amino benzonitrile
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
DE60313657T2 (de) 2002-11-08 2008-01-03 Smithkline Beecham Corp. Antivirale zusammensetzungen
CN100457754C (zh) 2002-11-15 2009-02-04 泰博特克药品有限公司 作为抗感染化合物的取代的吲哚吡啶
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
WO2005123076A2 (en) 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
SI1632232T1 (sl) 2004-09-02 2011-09-30 Janssen Pharmaceutica Nv Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
CA2587710C (en) 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP2008538754A (ja) * 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
BRPI0614455A2 (pt) 2005-07-28 2011-03-29 Isp Investments Inc efavirenz amorfo e a produção deste
TWI458483B (zh) 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
PL2040671T3 (pl) 2006-06-23 2018-08-31 Janssen Sciences Ireland Uc Wodne zawiesiny TMC278
WO2008060360A2 (en) * 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
CA2693044C (en) 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
WO2010047819A1 (en) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives

Also Published As

Publication number Publication date
JP2015044839A (ja) 2015-03-12
AU2004268390A1 (en) 2005-03-10
EP1663240B1 (en) 2015-04-22
CN101060844B (zh) 2012-01-04
NL300768I2 (nl) 2023-08-09
NO2014031I1 (no) 2015-01-05
US20190216807A1 (en) 2019-07-18
AU2011201123A1 (en) 2011-04-07
LTPA2016045I1 (lt) 2017-01-10
NO334877B1 (no) 2014-06-23
JP5820045B2 (ja) 2015-11-24
US20200171027A1 (en) 2020-06-04
US20180228800A1 (en) 2018-08-16
CY2015040I2 (el) 2016-08-31
KR20060090658A (ko) 2006-08-14
MXPA06002437A (es) 2006-06-20
CY2015038I2 (el) 2016-08-31
FR15C0073I2 (fr) 2016-02-12
JP5507791B2 (ja) 2014-05-28
NO2014030I1 (no) 2015-01-05
LU92853I2 (fr) 2015-12-21
AU2004268390B2 (en) 2011-03-31
CY2016048I2 (el) 2017-07-12
CY2015039I2 (el) 2016-08-31
HRP20150798T4 (hr) 2023-06-09
NO2014030I2 (no) 2014-12-18
CY2015039I1 (el) 2016-08-31
BE2015C053I2 (no) 2023-12-14
EP1663240B2 (en) 2023-03-01
US8841310B2 (en) 2014-09-23
LTPA2016044I1 (lt) 2017-01-10
IL213104A (en) 2016-02-29
JP2007520443A (ja) 2007-07-26
NO2014032I1 (no) 2015-01-05
CY2016049I1 (el) 2017-07-12
FR15C0071I2 (fr) 2016-02-12
HK1092698A1 (en) 2007-02-16
NL300781I2 (no) 2016-04-19
US20080200435A1 (en) 2008-08-21
FI1663240T4 (fi) 2023-04-25
PL1663240T5 (pl) 2024-02-26
CA2537095A1 (en) 2005-03-10
US20170100398A1 (en) 2017-04-13
US20150283135A1 (en) 2015-10-08
HUS1500053I1 (hu) 2016-03-29
EP1663240A1 (en) 2006-06-07
IL173438A (en) 2012-03-29
NL300781I1 (no) 2016-04-19
US20100029591A1 (en) 2010-02-04
AU2014203484B2 (en) 2016-09-29
CY2015038I1 (el) 2016-08-31
NO2016026I1 (no) 2016-12-20
CA2537095C (en) 2012-05-29
AP2006003551A0 (en) 2006-04-30
FR15C0073I1 (no) 2015-04-12
JP2012051915A (ja) 2012-03-15
US20220008417A1 (en) 2022-01-13
FR15C0071I1 (no) 2015-04-12
AU2014203484A1 (en) 2014-07-17
NO2014031I2 (no) 2014-12-18
AP2109A (en) 2010-02-26
HUS1600059I1 (hu) 2017-02-28
FR15C0072I2 (fr) 2019-05-17
PL1663240T3 (pl) 2015-10-30
HUS1500054I1 (hu) 2016-03-29
LTC1663240I2 (lt) 2022-05-25
CY2016048I1 (el) 2017-07-12
AU2016210733B2 (en) 2018-11-08
CY2015040I1 (el) 2016-08-31
IL213104A0 (en) 2011-07-31
NO20061374L (no) 2006-03-27
WO2005021001A1 (en) 2005-03-10
HUS1500052I1 (hu) 2016-03-29
LU92854I2 (fr) 2015-12-21
US20140349971A1 (en) 2014-11-27
NO2014032I2 (no) 2014-12-18
IL173438A0 (en) 2006-06-11
NZ545306A (en) 2009-11-27
FR15C0072I1 (no) 2015-04-12
AU2011201123B2 (en) 2013-10-10
NL300768I1 (no) 2015-12-16
HRP20150798T1 (hr) 2015-09-11
HUS1600058I1 (hu) 2017-02-28
AU2019200813A1 (en) 2019-02-28
AU2016210733A1 (en) 2016-08-25
LU92855I2 (fr) 2015-12-21
CN101060844A (zh) 2007-10-24
CY2016049I2 (el) 2017-07-12
MY169670A (en) 2019-05-08

Similar Documents

Publication Publication Date Title
FR15C0071I1 (no)
BE2014C055I2 (no)
BE2014C027I2 (no)
BE2014C003I2 (no)
BE2013C075I2 (no)
BE2013C069I2 (no)
BE2013C067I2 (no)
BE2013C038I2 (no)
BE2013C036I2 (no)
BE2013C034I2 (no)
BE2011C030I2 (no)
BE2015C005I2 (no)
BE2012C053I2 (no)
AU2002316511A1 (no)
AU2002362930A1 (no)
AU2002327042A1 (no)
AU2002327736A1 (no)
AU2002329412A1 (no)
AU2002331433A1 (no)
AU2002332887A1 (no)
AU2002322913A1 (no)
AU2002337949A1 (no)
AU2002339901A1 (no)
AU2002340206A1 (no)
AU2002348177A1 (no)